The NUMY-06 Injection And COVID-19

Testing Summary

The compound called putative neuraminidase inhibitor NUMY-06 (independent/controlled variable) should be tested by injecting it into an infected rhesus monkeys (experimental group) as an injection buffered with a 4% solution of HEPES-HCL. Both the experimental group and non-injected rhesus monkeys (control group) will be exposed to the Omicron BA-5 virus. After a specific period of time when the infection takes effect, the symptoms will be measured, such as shortness of breath, sense of taste and smell, and fever. The model organism for the experiment will be rhesus monkeys due to their exceptional similarity to humans and the fact the virus can infect them as well. The measurements from both groups will be compared for the effectiveness and impact of NUMY-06. If the results show a statistically significant change, the experiment can be repeated for other variants in a similar fashion.

Experiment Details

  1. The experimental variable in the experiment is the NUMY-06 injection.
  2. The dependent variable is a set of measurable COVID-19 symptoms, such as shortness of breath, sense of taste and smell, and fever.
  3. The control group is comprised of rhesus monkeys, which were not given putative neuraminidase inhibitors, but were exposed to the Omicron BA-5 virus.
  4. The use of a placebo is not necessary since the subjects are not humans, which means the monkeys do not have potentially biased expectations for a specific outcome to account for in the experiment.
  5. The appropriate number of rhesus monkeys used for the experiment should be 100 for the control group and 100 for the experimental group to have a strong statistical significance and confidence.
  6. The term basic indicates a higher than normal pH value, where low pH is considered acidic, and high pH is basic.